Fundraising FoxEnavate Sciences — Full Portfolio
16 tracked investments · listed companies and verified rows first
Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.
BiotechHealthtechMedical Devices
Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)
Co-investorsAtlas VentureOrbiMedRA CapitalViking Global
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Healthcare Investments+6 more
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.
BiotechHealthtechCambridge, US
Schuetz Thomas(Executive Officer, Director)inErrik Anderson(Executive Officer, Director)inThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNeil Lerner(Senior Vice President, Chief Accounting Officer)in
Co-investorsAlumni VenturesBioBritF-Prime CapitalForesite CapitalGV (Google Ventures)OrbiMed+4 more
Immunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer.
BiotechHealthtechExton, US
Scott K. Dessain(Executive Officer, Director)inDennis H Giesing(Executive Officer)inCorleen Roche(Executive Officer)inMichael J Morin(Executive Officer)Purnanand Sarma(Executive Officer, Director)inGeorge Hobbs(Executive Officer)
Co-investorsBioAdvanceDelaware Crossing Investor GroupEvolution VC PartnersMilitia Hill VenturesPivotal Life SciencesRobin Hood Ventures+1 more
Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.
BiotechHealthtechWaltham, US
LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in
BoardPATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)
Co-investorsDelos CapitalLongitude CapitalNew Enterprise Associates (NEA)Norwest Venture PartnersPivotal Life SciencesQuan Capital+4 more
Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Michael Tolentino(Executive Officer, Director)inMohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inDerek Kunimoto(Executive Officer)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in
Co-investorsJeito CapitalLongitude CapitalCatalio Capital Management, LPOrbiMedAvoro Capital AdvisorsDigitalis Ventures+1 more
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+7 more
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.
BiotechDeep TechMedical DevicesMenlo Park, US
Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers
BoardMatthew Young(Director)inSrinivas Akkaraju(Director)
Co-investorsAscenta CapitalLongitude CapitalSamsara BioCapitalF-Prime Capital
Ambros Therapeutics is a therapeutics company.
BiotechHealthtechSan Diego, US
Joseph (Jay) Hagan(President and Chief Executive Officer)
Co-investorsLifeSci Venture PartnersRA CapitalBAM ElevateJanus Henderson InvestorsPatient Square Capital
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.
BiotechDigital HealthHealthtechMedical Devices
Travis Murdoch, M.D.(Chief Executive Officer and Board Director)in
Co-investorsAndreessen HorowitzFrazier Life SciencesOrbiMedForbion
BridgeBio Oncology develops cancer therapies targeting tumors driven by RAS and PI3Kα signaling, using RAS signaling biology to design drugs that inhibit RAS-driven PI3K activation and a range of KRAS mutants in both their active (ON) and inactive (OFF) states.
BiotechHealthtech
Co-investorsAisling CapitalWellington Management
Camp4 is a biotechnology company focused on genetic research and neurology, leveraging expertise in genomics and neuroscience for therapeutic development.
AI & Machine LearningBiotech
Leonard Zon(Founder)Richard Young(Founder)
BoardChristopher Walsh, MD, PhD(Scientific Advisor)
Co-investors5AM VenturesAndreessen HorowitzFlucas VenturesNorthpond Ventures
Graviton offers an AI model trained on blockchain technology, including Solidity, to help developers build Web3 decentralized applications (dApps) from a prompt.
AI & Machine LearningCrypto & Web3Developer Tools
Co-investorsBlueYard CapitalPontifax Venture Capital
Graviton develops immunomodulatory therapies for patients with fibrotic, autoimmune, and central nervous system diseases.
AI & Machine LearningBiotechDeep TechHealthtechNew York, US
Samuel Waksal(Founder & CEO)Steven Gordon(Executive Officer, Director)
BoardPhilip Barach(Director)Richard Giroux(Director)
Co-investorsInnova Capital Partners, LLCPontifax Venture Capital
Patient Square Capital is a healthcare investment firm managing $19 billion in assets that partners with growth-oriented companies developing products, services, and technologies to improve patient health outcomes.
Healthtech
Co-investorsBCI
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)inScott Byrd(Executive Officer, Director)in
Co-investorsFrazier Life SciencesMonograph Capital PartnersMSA NovoPICUS CAPITALSanofi VenturesSV Health Investors+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.